Obesity is associated with chronic, low-grade inflammation, which can disrupt homeostasis within tissue microenvironments. Given the correlation between obesity and relative risk of death from cancer, we investigated whether obesity-associated inflammation promotes metastatic progression. We demonstrate that obesity causes lung neutrophilia in otherwise normal mice, which is further exacerbated by the presence of a primary tumour. The increase in lung neutrophils translates to increased breast cancer metastasis to this site, in a GM-CSF-and IL5-dependent manner. Importantly, weight loss is sufficient to reverse this effect, and reduce serum levels of GM-CSF and IL5 in both mouse models and humans. Our data indicate that special consideration of the obese patient population is critical for effective management of cancer progression.
. Beyond the local tumour microenvironment, an inflammatory systemic environment can also affect disease outcome, by perturbing homeostasis within multiple tissues throughout the body 3 . This becomes particularly important during metastasis, where systemic alterations can modify the tissue landscape of distant organs and support tumour cell colonization by establishing a pre-metastatic niche 4 . Indeed, chronic inflammation can increase cancer risk and/or progression 5 . Investigation into how the systemic environment affects tumour biology is therefore critical for an integrated understanding of cancer 3 . A prevalent and clinically relevant example of systemic inflammation is obesity, which affects >30% of adults in the US, and is linked to multiple pathologies, including cancer 6 . As a growing epidemic, obesity now rivals smoking as the leading preventable cause of cancer 7 . Obesity-associated inflammation is driven in part by adipocyte-myeloid cell interactions within various fat depots, resulting in altered immune cell composition in different tissues [8] [9] [10] [11] [12] . Thus, an emerging hypothesis is that obesity-associated inflammation promotes cancer progression 11 , aligning with well-established associations between other chronic inflammatory conditions and tumorigenesis 13 .
Clinical analyses have shown that obesity is associated with higher incidence of breast cancer metastasis 14 , particularly to liver and lung 15 . However, insight into the mechanisms underlying obesity-induced metastasis, compared with the effects on primary tumour growth 16 , has been limited. Of particular interest is lung metastasis, given the high frequency of breast cancer dissemination to this site in patients 17 , and the strong clinical association between obesity and multiple lung-inflammatory conditions 18, 19 , despite the lack of adipose tissue within the lung. Therefore, we sought to analyse the effects of obesity-associated inflammation on breast-to-lung metastasis using animal models, focusing on myeloid cell populations given their role during adipose inflammation 20 and pulmonary metastasis in nonobese settings [21] [22] [23] [24] [25] [26] [27] [28] [29] .
RESULTS

Obesity is associated with lung neutrophilia driven by high adiposity
To investigate the effects of obesity on lung inflammation, we used a diet-induced obesity (DIO) model; wild-type (WT) C57 black6 (BL6) female mice were enrolled on either a low-fat (LF; 10% kcal) or highfat (HF; 60% kcal) diet for 15 weeks followed by immunoprofiling. We found HF lungs exhibited elevated proportions of CD45 + leukocytes Figure 1 Obesity is associated with lung neutrophilia driven by adiposity. (a) Weight curves for the diet-induced obesity (DIO) model. 5-week-old female BL6 mice were fed a low-fat (LF) or high-fat (HF) diet for 15 weeks. LF, n = 8 mice; HF, n = 10 mice; mean ± s.e.m. (b) Left, flow cytometry of lung myeloid cells in the DIO model at 15 weeks. LF, n = 8 mice; HF, n = 10 mice; minimum-maximum boxplots, all data points shown. Right, CD11b + Gr1 + populations are shown as a red overlay on total CD11b + cells, graphed on Ly6C (x axis) by Ly6G (y axis) dot plots. (c) Weight curves for the leptindeficient genetic model of obesity (ob/ob). Female ob/ob or wild-type (WT) mice were fed a normal diet until the pre-defined weight endpoint of >40 g. n = 10 mice per group; mean ± s.e.m. (d) Left, flow cytometry of lung myeloid cells in the ob/ob model at 6 weeks. Representative plots (right) are displayed as in b. n = 10 mice per group; minimum-maximum boxplots, all data points shown. (e) Weight curves for the obesity-resistant Balb/c model. 5-week-old female Balb/c mice were fed a LF or HF diet for 15 weeks. n = 10 mice per group; mean ± s.e.m. (f) Left, flow cytometry of lung myeloid cells in the Balb/c model at 15 weeks. Representative plots (right) are displayed as in b. n = 10 mice per group, minimum-maximum boxplots, all data points shown. (g) Weight curves for the diet-switch model. 5-week-old female BL6 mice were fed a HF diet over 15 weeks, and then switched to LF diet for an additional 7 weeks (HF-LF). HF, n = 6 mice; HF-LF, n = 11 mice; mean ± s.e.m. (h) Left, flow cytometry of lung myeloid cell subsets in the dietswitch model. Representative plots (right) are displayed as in b. HF, n = 6 mice; HF-LF, n = 11 mice, minimum-maximum boxplots, all data points shown. Significance was calculated via two-tailed unpaired Student's t-test throughout. NS, not significant. Box plots represent median and interquartile range while whiskers represent maximum and minimum values excluding outliers. Each symbol represents one mouse.
A R T I C L E S
(∼13-19% of total cells), CD11b + Gr1 − macrophages (∼3-4% of total cells) and CD11b + Gr1 + myeloid cells (∼2-7% of total cells) by flow cytometry (Fig. 1a,b Fig. 1b and Supplementary Fig. 1a ). Cytospin and Giemsa staining identified
CD11b
+ Gr1 + cells as predominantly hyper-segmented neutrophils ( Supplementary Fig. 1b ). Of note, we observed no changes in the proportions of bulk T lymphocytes (total CD3 + cells; ∼8-9% of total cells) or T-cell subsets (CD3 + CD4 + , ∼2-3% of total cells; CD3 + CD8 + , Fig. 1c ).
∼1-2% of total cells) in HF lungs (Supplementary
To uncouple whether this increase in lung neutrophils was due to high adiposity or diet content, we first analysed the ob/ob genetic model of obesity 30 , in which animals fed a normal diet exhibit rapid weight gain (Fig. 1c) due to hyperphagia secondary to leptin deficiency. Ob/ob lungs exhibited elevated proportions of neutrophils by flow cytometry, but no significant changes in overall leukocytes or macrophages (Fig. 1d) . In a reciprocal experiment, we employed a BALB/c model of obesity resistance, whereby WT BALB/c mice were fed HF or LF diet for 15 weeks, but did not gain weight (Fig. 1e) . Unlike most other mouse strains, this obesity-resistance phenotype is inherent to BALB/c animals 31 . We found no significant increase in neutrophils (Fig. 1f) , in contrast to results from DIO and ob/ob mice. These data suggest that the increase in lung neutrophils is due to high adiposity of obese animals, rather than diet/nutrient content.
We next profiled other common organs for breast cancer dissemination, including liver and brain. DIO mice exhibited no change in immune cell proportions in brain, including macrophages and neutrophils (Supplementary Fig. 1d and Supplementary Table 1) . While we detected a significant increase in neutrophil proportions in the liver, these differences were inversely correlated with the ob/ob model ( Supplementary Fig. 1e ), suggesting that the changes in this organ may be diet-dependent, unlike our findings in the lung (Fig. 1d) . We therefore focused subsequent experiments on the effects of adiposity on lung inflammation, and neutrophils specifically, as this was the only immune cell population consistently elevated in the lung across the different obesity models.
We next asked whether obesity-associated lung neutrophilia was reversible. Animals were enrolled on HF diet for 15 weeks, and switched to LF for an additional 7 weeks (Supplementary Fig. 1f ). Mice lost an average of 28% of their body weight over the diet-switch period (Fig. 1g) . Lung neutrophils decreased after diet-switching, compared with animals that remained on continuous HF diet (Fig. 1h) , indicating that obesity-associated lung neutrophilia is reversible with weight loss.
Obesity-associated lung neutrophilia is accompanied by pro-metastatic gene expression changes and enhanced metastatic progression It is known that neutrophils, defined as either CD11b + Gr1 +/hi or CD11b + Ly6G + by flow cytometry, are elevated in the pre-metastatic lung in PyMT breast cancer models, and become activated to support metastatic progression 24, 25, 27, 29 . We therefore asked whether lung neutrophils were activated in obese mice, and how this might affect breast cancer metastasis. We purified lung neutrophils from LF and HF animals (DIO model) using fluorescence-activated cell sorting (FACS), and performed quantitative PCR with reverse transcription (qRT-PCR) for a panel of markers relevant to neutrophil biology in cancer 32 . We focused on genes related to mobilization (Cxcl2, Cxcl12, Cxcr4, Cxcr2 and Tlr4 [33] [34] [35] ), 'N2-like' polarization (Arg1, Ccl5, Ccl2 and Tgfb1 36,37 ), immune suppression (Il10, Nox2, Nos2, Pge2, Ptgs2 and Pdl1 [38] [39] [40] ) and activation/expansion (Il1b and Nlrp3
41
, Alox5
24
, S100A9 and S100A8 42 ). Markers of N2-like polarization were significantly downregulated in HF neutrophils (Fig. 2a ), suggesting discordance with the 'N1/N2-like' paradigm 36 . We observed significant increases in several markers associated with mobilization (3/3 upregulated) and activation (4/5 upregulated), and variable changes in markers associated with immune suppression (2/6 upregulated and 1/6 downregulated; Fig. 2a ), indicating that HF neutrophils were phenotypically different from LF neutrophils, in addition to being more abundant. Interestingly, many gene expression changes in association with obesity were indicative of a pro-metastatic phenotype, for example, Alox5, S100a8/9 and Cxcr2/4 25, 33, 34, 42 . We next investigated whether the elevation in neutrophil number/activation during obesity was associated with enhanced lung metastasis. We generated a syngeneic immune-competent breast cancer model compatible with the BL6 DIO model, by isolating a panel of cell lines from BL6 MMTV-PyMT mice and confirming that they form orthotopic tumours that spontaneously metastasize to lung after ∼2 months ( Supplementary Fig. 2a-d) . Orthotopic transplantation of two of these lines (99LN, 86R2) into the DIO model revealed that primary tumour growth was modestly enhanced with HF feeding over a 2-month period ( Fig. 2b and Supplementary Fig. 2e ). Systemic neutrophilia was monitored at different time points: prior to tumour cell injection (0 d), when tumours were palpable (14 d), during early phases of primary tumour growth (28 d; pre-metastatic niche) and late phases of primary tumour growth (56 d; micro-metastatic disease). At 0 d, circulating neutrophils were elevated in HF versus LF mice, and as primary tumours grew, a significant difference in neutrophilia was maintained (Fig. 2c) . At early phases of primary tumour growth (28 d), we quantified neutrophils in the pre-metastatic lung, and found that while lean tumour-bearing mice exhibited lung neutrophilia compared with lean non-tumour-bearing mice (as has been reported 24, 25, 27, 29, 37, 43, 44 ), obesity significantly enhanced neutrophilia in the tumour-bearing setting (Fig. 2d) . At the trial endpoint (56 d), we found elevated micro-metastases in the lung ( Fig. 2e and Supplementary Fig. 2f ), concomitant with increased lung neutrophilia in obese compared with lean mice (Fig. 2d) . These data indicate that obesity enhances spontaneous lung metastasis, and contributes to lung neutrophilia in a manner that is additive to pre-metastatic niche observations obtained in standard (lean) mouse models.
Obesity enhances experimental breast cancer metastasis to lung in a neutrophil-dependent manner Given the differences in primary tumour volumes between HF and LF mice, we investigated whether obesity affects experimental metastasis of breast cancer cells via tail vein injection. We labelled 99LN cells with luciferase-GFP, to allow for bioluminescent imaging (BLI) and flow cytometry, and monitored experimental lung metastasis over 5 weeks. HF mice exhibited significantly higher luminescence in the lung compared with LF mice after 5 weeks (Fig. 3a,b) , which was confirmed by flow cytometry for GFP + tumour cells (Fig. 3c) . Moreover, we found that the increased proportion of neutrophils during obesity was also evident in the tumour-bearing setting (Fig. 3d) .
Given the roles of neutrophils in establishing a pre-metastatic niche 25, 27, 29 and influencing early seeding 24, 43 , we examined the effects of obesity on earlier metastatic time points 45 . We analysed lung metastasis 48 h following tail vein injection of 99LN cells into the DIO model. HF mice exhibited significantly higher luminescence in the Figure 2 Obesity-associated lung neutrophilia is accompanied by prometastatic gene expression changes and enhanced metastatic progression.
(a) qRT-PCR on whole lung, bone marrow (BM) or FACS-purified lung neutrophils from HF non-tumour-bearing mice. Data are displayed as log 10 (fold change) relative to LF (centre normalized line). BM and whole lung, n = 5 mice; lung neutrophils, n = 4 mice. * P < 0.05, * * P < 0.01, * * * P < 0.001. lung compared with LF mice (Fig. 3e) , consistent with flow cytometry of GFP + tumour cells (Fig. 3f) . Immunoprofiling of lung showed that obesity-induced neutrophilia was evident in this early metastatic setting (Fig. 3g ). Similar observations were made for experimental metastasis in the ob/ob model ( Supplementary Fig. 3a,b) , where expression analysis revealed an upregulation of pro-metastatic genes in ob/ob lung neutrophils compared with WT ( Supplementary Fig. 3c ).
Given the short duration of the 48 h experimental metastasis model, we suspected that neutrophils affect pro-metastatic processes beyond suppression of the adaptive immune response, as is frequently reported for CD11b + Gr1 + myeloid-derived suppressor cells 25, 27, 32 . In co-culture experiments, HF neutrophils did not exhibit an enhanced capacity to modulate cytotoxic T-cell proliferation or NK cell degranulation in vitro ( Supplementary Fig. 3d-f ), nor did we observe enhanced NK cell suppression in vivo (Supplementary Fig. 3g ). These findings suggest that HF neutrophils are not immunosuppressive, unlike their myeloid-derived suppressor cell counterparts, and affect early metastatic seeding; therefore, we restricted further analyses to the 48 h metastasis model. Next, we assessed whether neutrophils were functionally important during obesity-associated lung metastasis. We used a neutralization antibody against Gr1 (clone RB6-8C5 9 ), and confirmed treatment efficacy in blood, lung and spleen ( Supplementary Fig. 4a-c) . Using the 48 h experimental metastasis assay, we found that Gr1 neutralization in HF mice significantly reduced lung metastasis compared with IgG controls, confirmed by BLI and flow cytometry (Fig. 3h,i ). These data demonstrate that obesity-associated lung neutrophilia supports subsequent metastatic seeding.
Elevated GM-CSF in serum underlies obesity-associated lung neutrophilia and breast cancer metastasis
We next asked how lung neutrophil numbers are elevated during obesity. Blood analyses of LF and HF animals revealed enhanced neutrophilic leukocytosis associated with HF feeding (Fig. 4a) , consistent with reported findings from human subjects with high body mass index (BMI) 46 , and with the orthotopic trial results (Fig. 2c) . We hypothesized that circulating factors may contribute to regulating this systemic inflammatory phenotype, and collected serum from Mouse serum (5%) LF and HF mice for in vitro myelopoiesis assays. Intriguingly, HF serum supported differentiation of bone marrow (BM) towards a CD11b + Gr1 + phenotype more effectively than LF serum (Fig. 4b ). Critically, we confirmed this result with serum from obese and lean human donors (Fig. 4c) .
To identify serum factors supporting myelopoiesis, we performed a cross-species cytokine screen of 103 factors, using serum from both mice and humans (Supplementary Table 2 ). Thirty factors were enriched in mouse HF serum compared with LF serum, and 16 factors were enriched in human obese serum compared with lean serum. Of these, 8 were upregulated in both species, including CCL25, CD40L, GM-CSF, IGFBP2, IL5, IL6, MMP3 and MMP9 ( Fig. 4d and Supplementary Fig. 5a-d ). Using recombinant proteins in the in vitro myelopoiesis assay, we found that only GM-CSF was capable of enhancing differentiation towards a CD11b + Gr1
+ phenotype (Fig. 4e ). Antibody-mediated neutralization of GM-CSF in the context of HF serum reduced CD11b + Gr1 + differentiation in vitro, to a level comparable to LF serum ( Fig. 4f) , demonstrating the necessity of this factor.
Intriguingly, analysis of GM-CSF (Csf2) expression by qRT-PCR of bulk tissues from obese mice revealed a marked enrichment in whole lung compared with spleen, blood, BM, liver and fat ( Fig. 4g and Supplementary Fig. 5e-k) . This is consistent with Csf2 mouse knockout studies demonstrating a tissue-specific role for GM-CSF in lung physiology and inflammation [47] [48] [49] . Moreover, in FACS-purified cell populations from obese lungs, Csf2 was expressed by multiple immune cell types including various myeloid cells (for example, Ly6C hi monocytes), and CD3 + bulk T cells (Fig. 4h) , suggesting that maintenance of neutrophils in the lung is due to both autocrine signalling and paracrine interactions with additional immune cell populations. These data implicate GM-CSF as a regulator of lung neutrophilia in the context of obesity.
To test whether GM-CSF alone was capable of recapitulating obesity-induced lung neutrophilia in vivo, we treated WT animals with recombinant (r) GM-CSF for 5 d, followed by flow cytometry analysis. Even after this short time period, there was a significant increase in the proportion of neutrophils in blood and lungs in response to rGM-CSF compared with controls ( Fig. 5a ). This result is consistent with previous reports showing that GM-CSF regulates lung neutrophilia in models of pulmonary alveolar proteinosis, asthma, bronchitis and pulmonary infection 18, [48] [49] [50] . Significant differences in neutrophil numbers within immune reservoirs such as the spleen or BM were not observed during this short experimental time course ( Supplementary Fig. 6a ,b), suggesting that this change was not driven by neutrophil expansion within those depots.
We next asked whether GM-CSF was sufficient to modulate metastatic outcome in vivo. We treated WT animals on a normal diet with rGM-CSF for 5 d to induce neutrophilia ( Fig. 5a ), followed by a 48 h experimental metastasis assay using 99LN breast cancer cells injected intravenously (Fig. 5b ). We observed a significant increase in metastases, as measured by BLI in the lung at 48 h, in animals treated with rGM-CSF compared with PBS controls (Fig. 5c ). In a reciprocal experiment, we enrolled animals on either a HF or LF diet for 15 weeks, followed by antibody-mediated neutralization of GM-CSF prior to injecting 99LN cells intravenously ( Fig. 5d) . At the trial endpoint of 48 h we found that GM-CSF neutralization in HF-fed animals, but not LF animals, resulted in a significant decrease in lung BLI compared with IgG control (Fig. 5e ), corroborating our Gr1-neutralization results (Fig. 3h,i) . These results were validated by flow cytometry of GFP + tumour cells in lung ( Fig. 5f ). Importantly, when we immunoprofiled the lungs, we found that the proportion of neutrophils was significantly reduced in HF animals after GM-CSF neutralization compared with IgG, but this effect was not observed for LF animals (Fig. 5g) . Together, these results demonstrate that obesity-associated GM-CSF is critical to support lung neutrophilia and enhanced metastatic seeding.
We then asked whether serum GM-CSF was elevated in response to a primary tumour, as reported for the related factor G-CSF 25, 27, 29 . Enzyme-linked immunosorbent assay (ELISA) for GM-CSF in serum isolated from the orthotopic experiments showed a modest (non-significant) increase in GM-CSF in lean mice in response to the presence of a primary tumour; this effect was significantly increased with obesity, and even more pronounced during later stages of progression (Fig. 5h ). These data indicate that obesity may exacerbate the stimulatory effects of a primary tumour on neutrophils.
IL5 signalling supports obesity-associated lung neutrophilia
We next explored how obesity induces GM-CSF expression. From our findings in ob/ob and Balb/c mice ( Fig. 1c-f ), we determined that adiposity was an important contributor to lung neutrophilia. Therefore, we investigated which of the 8 upregulated factors from the cytokine array (Fig. 4d) were specifically enriched in adipose tissue. We found that Il5 expression was enriched in both subcutaneous and visceral fat in obese animals ( Fig. 6a) , and highest in adipose tissue compared with spleen, blood, BM, liver and lung ( Supplementary  Fig. 5e ). IL5 plays a canonical role in regulating eosinophils, another type of granulocyte, during allergic asthma 19, 51 . Given the link between obesity and adult-onset asthma 19 , we wanted to determine the relevance of IL5 to neutrophil regulation. In WT animals, treatment with rIL5 for 5 d significantly increased the proportion of lung neutrophils compared with PBS controls (Fig. 6b, 
c). CD3
+ T cells, another GM-CSF-producing cell population in the lung (Fig. 4h) , were also elevated in response to rIL5 ( Supplementary Fig. 7a ). Furthermore, increased neutrophils led to enhanced experimental lung metastasis, which was blocked by GM-CSF neutralization (Supplementary Fig. 7b-d ). These data suggest that neutrophils are in part regulated by IL5, either by direct or indirect mechanisms.
We next determined which cell types respond directly to IL5, by identifying populations that express the IL5 receptor. The IL5 receptor has an alpha-subunit (IL5rα) and beta-subunit (Csf2rβ). Interestingly, the beta-subunit is shared between IL5, GM-CSF and IL3; a reflection of their complementary roles during airway inflammation and Th2 immunity in asthma 52 . Csf2rβ is broadly expressed on myeloid cells, and induces signal transduction in response to IL5, while IL5rα expression is more limited and dictates cellular specificity of IL5 signalling. Most of the literature on IL5rαup is focused on expression by eosinophils (reviewed in ref. 53), with only a few studies reporting eosinophil-independent effects of IL5 [54] [55] [56] . However, by flow cytometry we determined that 99% of neutrophils and 68% of monocytes isolated from HF peripheral blood express IL5rα, as compared with CD11b + SSC hi SiglecF + eosinophils, which were 100% positive for IL5rα as expected (Fig. 6d ). When we quantified Csf2ra, Csf2rb and Il5ra expression in FACS-purified IL5rα + lung neutrophils, eosinophils and monocytes from the DIO model, we found that in several instances, the genes encoding these receptor subunits were upregulated by obesity (Fig. 6e) . This is consistent with reports of upregulated Il5ra in neutrophils and monocytes in response to sepsis-associated inflammation 54 , and methylation analyses that predicted IL5RA upregulation in circulating immune cells in response to obesity in humans 57 . Corroborating these results, by flow cytometry we found a subset of IL5Rα + intermediate monocytes from human blood (mean = 23.4% positive), as well as a smaller proportion of neutrophils (mean = 12.2% positive), classical monocytes (mean = 12.3% positive), and non-classical monocytes (mean = 11.8% positive) when eosinophils were used as a positive gating control (Fig. 6f) . We were unable to detect Il5ra expression by qRT-PCR on CD3 + T cells isolated from lungs in the DIO model. However, given our findings that CD3 + T cells isolated from obese lung tissue express Csf2 (Fig. 4h) , and the increase in CD3 + T-cell numbers in the lung following rIL5 treatment in vivo ( Supplementary Fig. 7a ), we wanted to directly test whether T cells were important for IL5-mediated lung neutrophilia. We treated athymic nude mice with rIL5 for 5 d, and found that lung neutrophilia in response to IL5 treatment did not occur in the absence of T cells ( Supplementary  Fig. 7e ). In addition, the proportion of IL5rα + myeloid cells in nude mice was significantly reduced compared with BL6 mice (monocytes reduced from 68% to <1%; neutrophils 99% to 9%; eosinophils 100% to 90%; Supplementary Fig. 7f ). Similar results were observed in NOD-scid Il2rg null (NSG) mice, which lack mature T, B and NK cells ( Supplementary Fig. 7e,f) . Taken together, our findings indicate that T cells are indispensable for IL5-induced lung neutrophilia.
We next asked which IL5rα + cell type was capable of mediating a functional response to IL5. We FACS-purified IL5rα + cells from the peripheral blood of BL6 mice, including monocytes, neutrophils and eosinophils, and treated them in vitro with rIL5. Not surprisingly, by flow cytometry we observed increased Ki67
+ proliferating IL5rα + eosinophils in response to rIL5 (Fig. 6g )-a canonical effect of IL5 in this cell type. We also found increased proliferation of IL5rα + monocytes in response to rIL5 in vitro (Fig. 6g) , concomitant with upregulated Csf2 expression by qRT-PCR (Fig. 6h) . In the DIO model, we confirmed that obesity increases IL5rα + monocyte abundance in blood and lung, concomitant with an increase in Csf2 expression, compared with LF controls (Fig. 6i,j) . These data indicate that IL5rα + monocytes directly respond to IL5 by expanding in numbers and producing GM-CSF, and may thereby contribute to lung neutrophilia during obesity.
Obesity enhances lung homing of neutrophils in an IL5-dependent manner
Given that HF lung neutrophils upregulate genes associated with mobilization ( Fig. 2a) , such as Tlr4, Cxcr2 and Cxcr4 33-35 , we asked whether obesity alters homing and/or retention of neutrophils in the lung, and whether this is dependent on IL5. We isolated and fluorescently labelled neutrophils from BM of WT (green) and ob/ob (red) donors, mixed them 1:1, and performed adoptive cell transfer back into WT, ob/ob or ob/ob + anti-IL5 recipients (Fig. 7a,b) . We found that 4 h post-adoptive transfer, the majority of labelled neutrophils in the lung across all recipient groups were from ob/ob donors (Fig. 7c,d) , despite equivalent proportions of WT and ob/ob neutrophils in blood (Fig. 7e) , indicating that neutrophils from obese animals are predisposed to lung homing. Furthermore, lung trafficking of ob/ob donor neutrophils was significantly enhanced in ob/ob recipients compared with WT recipients, and this effect was mitigated by IL5 neutralization (Fig. 7c) . This suggests that obesity primes the lung microenvironment to support neutrophil homing in an IL5-dependent manner. After 8 h, neutrophil clearance within the lungs and blood was comparable between donor groups ( Supplementary Fig. 8a,b) ; however, ob/ob recipient animals retained the highest levels of lung neutrophils regardless of donor genotype (Fig. 7f,g ). Interestingly, this capacity for neutrophil retention was blocked by IL5 neutralization (Fig. 7f,g ). These data indicate that obesity supports increased lung homing and retention of neutrophils in an IL5-dependent manner.
Weight loss reduces obesity-associated lung neutrophilia and metastasis Given our observation that diet-switch reverses obesity-induced lung neutrophilia in the DIO model (Fig. 1g,h) , and the relevance of this non-invasive intervention strategy to patients, we investigated whether weight loss could similarly reduce obesity-associated metastasis. We confirmed that IL5rα + neutrophils and monocytes were upregulated in HF lungs, which was reversed by diet-switching (Fig. 8a-c) . We found that diet-switching reversed experimental lung metastasis (Fig. 8d) , and the expression of key markers of neutrophil activation/mobilization, including Cxcr2 and S100A8 (Fig. 8e) . Finally, serum analysis by ELISA showed reduced GM-CSF and IL5 in diet-switched mice, compared with mice fed continuous HF diet (Fig. 8f) . These data indicate that diet changes in association with weight loss may be sufficient to reverse the pro-metastatic effects of obesity.
Finally, we asked whether weight loss intervention was sufficient to reduce key serum factors identified here (that is, GM-CSF, IL5) in a human clinical trial. We obtained matched serum samples from 10 female obese humans before and after 10% weight loss by caloric restriction 58 (ClinicalTrials.gov Identifier: NCT01699906). Consistent with results from the DIO model, there was a significant decrease in circulating neutrophils with weight loss 58 , corroborating observations of reduced leukocytosis following bariatric surgery in obese humans 59 . Following assessment of serum levels of GM-CSF and IL5 in matched individuals, we found that these factors were generally reduced following weight loss (Fig. 8g) , Similarly, weight loss resulting from surgical intervention has been shown to reduce serum levels of GM-CSF and IL5 in accordance with a reduction in BMI
60
. These results demonstrate the potential translational relevance of our findings to humans, and indicate that weight loss interventions may be useful to improve outcomes in obese breast cancer patients.
DISCUSSION
In this study, we have identified lung neutrophilia as a secondary effect of obesity. This occurs independently of diet; rather it is directly related to increased adiposity and the expression of IL5 by adipose tissue. IL5 has been reported as a negative regulator of adipose tissue expansion and insulin resistance 61 , thereby working to constrain the effects of obesity on metabolism. While in adipose tissue IL5 supports homeostasis 62 , the increase in serum IL5 has the opposite effect on lung. We found that IL5 increases Csf2 expression by IL5rα + monocytes, and neutrophil trafficking to lung. Furthermore, increased serum GM-CSF promotes myelopoiesis, leading to an expansion of peripheral neutrophils (Fig. 8h) . Collectively these findings demonstrate that obesity causes lung inflammation, despite the lack of adipose tissue in this organ, by acting through the systemic environment.
In tumour models, we showed that obesity-associated lung neutrophilia enhances breast cancer metastasis to this organ, and that depletion of Gr1 + cells in obese animals reverses this effect. This is reminiscent of the pre-metastatic niche concept 4 , although in this case the elevation of pro-metastatic neutrophils is observed in non-tumour-bearing animals, and exacerbated by the presence of a primary tumour. Of particular interest was our observation that GM-CSF is predominantly expressed by lung in obese mice, and that GM-CSF blockade reverses the pro-metastatic effects of obesity. This suggests that disruption of normal lung homeostasis is a critical intermediary of obesity-induced metastasis, and that pharmacological interventions that resolve lung inflammation may reduce metastatic risk. However, neutrophil depletion is unlikely to be a safe option for patients. Alternatively, we have shown that targeting IL5 is sufficient to block lung neutrophil trafficking in obese mice; this strategy could be used to normalize the lung microenvironment without causing systemic neutropenia. Indeed, clinical evaluation of anti-IL5 therapy has confirmed the safety and efficacy of this approach in resolving eosinophilic asthma in patients, including the morbidly obese 63 . Our data suggest that obesity remains coupled to the pathological state of the lung, and that restoration of homeostasis within the adipose tissue through weight loss interventions will similarly normalize the lung microenvironment. In humans, we found that 10% weight loss in morbidly obese individuals was associated with reduced serum IL5 and GM-CSF, concomitant with decreased circulating neutrophils
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. This is consistent with observations that caloric restriction reverses obesity-associated inflammation within mammary tissue 64 , and enhances anti-tumour immunity 65 . Our findings also have implications for the long-term management of obese breast cancer patients, as pulmonary inflammation may have prognostic value. Monitoring serum levels of GM-CSF, IL5 or absolute neutrophil counts could prove useful to stratify the obese patient population, and identify those at highest risk of metastasis who may benefit from obesity-specific adjuvant therapies or dietary interventions. Clinical studies are therefore warranted to appropriately manage the obese cancer patient population, and uncouple the comorbidity of obesity and cancer.
While we have identified GM-CSF and IL5 as two critical cytokines that mediate obesity-enhanced lung metastasis in breast cancer, it is likely that additional factors are involved. Identifying drivers of the pro-metastatic phenotype of lung neutrophils in the context of high adiposity, and how the primary tumour influences these mechanisms, are important questions for future studies. Furthermore, it is unclear how an increase in circulating IL5 is achieved during obesity, and whether this affects other organs besides lung and adipose tissue. Given the importance of Th2 cytokines in promoting cancer progression in a primary tumour microenvironment 1 , a greater understanding of how IL5 affects breast cancer within adipose tissue of the obese mammary gland is warranted. Clinical translation of microenvironment-targeting agents has been hindered by patient heterogeneity and challenges in identifying individuals that will derive benefit. Investigating the effect of comorbidities, in this case obesity, on the microenvironment and cancer progression represents an important new direction in the field.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. 
Cell lines. The MMTV-PyMT mouse model was backcrossed into the BL6 background for >10 generations prior to isolating breast tumour cell lines. These cell lines were subsequently selected for their capacity to grow in the mammary fat pad (7 × 10 5 cells injected per mouse) of WT BL6 animals within a reasonable time period (<2 months). Three cell lines were selected for subsequent experiments, including 99LN, 86R2 and 91R2. All breast tumour cell lines in culture were maintained in DMEM supplemented with 10% FBS, and were validated to be mycoplasma-free. For assays involving immune cell culture, primary cells were isolated from peripheral sources (that is, blood or bone marrow) by FACS and used immediately for functional assays, for example NK cell co-culture or T cell CFSE, as described below.
Biological reagents and specifications. Reagents for in vitro use were as follows: recombinant proteins (CCL25, CD40L, GM-CSF, IGFBP2, IL5, IL6, MMP3, MMP9, 100 ng ml −1 for all; R&D Systems); antibody-mediated neutralization of GM-CSF (IgG versus anti-GM-CSF, 0.1 µg ml −1 ; R&D Systems). Reagents for in vivo use were as follows: antibody-mediated neutralization of Gr1 (6 µg Ob/ob model. To control for the effects of adipose tissue content in mice, 4-week-old female B6.Cg-Lep ob (ob/ob; Jackson Laboratory) mice were purchased and maintained on normal rodent diet. These mice gain weight due to a homozygous mutation in the leptin (Lep) gene that causes excessive eating and rapid weight gain. Weight was monitored over time beginning at 5 weeks old, and mice were euthanized when they reached >40g. This time period was significantly shorter (6 weeks) than that of the DIO model (15 weeks). After 6 weeks, animals were euthanized for flow cytometry analysis of myeloid cell populations in the lung, or injected with tumour cells for 48 h metastasis assays (see 'Experimental metastasis assay' section).
Balb/c obesity-resistant model. To control for the effects of nutrient content in diet, 5-week-old WT Balb/c mice (Jackson Laboratory) were enrolled on either HF or LF diet (Research Diets, see 'DIO model') for 15 weeks. Balb/c animals do not gain weight in response to HF feeding 31 . After 15 weeks, animals were euthanized for flow cytometry analysis of myeloid cell populations in the lung.
Immune-compromised mouse models. Two immune-compromised mouse models were used in this study, athymic nude (lack T cells) and NOD-scid Il2rg null (NSG; lack mature T, B and NK cells). In both cases, 5-week-old female mice (Jackson Laboratory) were treated with recombinant mouse IL5 (8 µg kg −1 body weight, dosed intraperitoneally every day for 5 d, 2% BSA/PBS vehicle control; BD Pharmingen) 68 , and flow cytometry was used to quantify lung neutrophils (CD45 + CD11b + Ly6C lo Ly6G + ), monocytes (CD45 + CD11b + Ly6C hi ) and eosinophils (CD45 + CD11b + SSC hi Siglec-f + ).
Flow cytometry and fluorescence-activated cell sorting (FACS).
For flow cytometry of tissues, mice were anaesthetized with avertin, blood was collected by submandibular bleeding, and cardiac perfusion with PBS was performed. All tissues were mechanically dissociated and filtered through a 40 µm mesh to generate a single-cell suspension, and red blood cells were lysed (Pharm Lyse; BD Biosciences). hi monocytes, and were therefore excluded from all neutrophil gating. OneComp eBeads (eBioscience) or ArC Amine Reactive Compensation Beads (Invitrogen) were used for compensation. A BD LSRFortessa was used for flow cytometry, and a BD FACSAria III was used for FACS. FlowJo was used for all flow cytometry and FACS data analysis, and for generating representative flow plots. For mouse cell gating strategy, in all cases, dead cells and debris were excluded from analyses using FSC × SSC, a live/dead stain and/or DAPI. CD45 + was used as a marker for total leukocytes; CD11b + was used as a marker for myeloid cells. Neutrophils were further defined as CD45 + CD11b + Gr1 +/hi or CD45 + CD11b + Ly6C lo Ly6G + . CD45 + CD11b + Gr1 lo cells were determined to be CD45 + CD11b + Ly6C hi monocytes, and were therefore excluded from all neutrophil gating. Eosinophils were defined as CD45 + CD11b + myeloid cells with high side scatter, and Siglec-f + . In some cases, further gating on IL5ra + or Ki67 + populations was performed for eosinophils, monocytes and neutrophils as defined here. T cells were gated as CD45 + CD3 + and then further gated according to positive CD4 or CD8 status for helper and cytotoxic T cells, respectively. For NK cell cytotoxicity assays, NK cells were defined as CD45 + with low side scatter, and NK1.1 + . Gating on CD107a + populations was used to further define NK cells with cytotoxic function. Primary tumour growth and spontaneous metastasis. To investigate the effects of obesity on breast cancer primary tumour growth, 1.5 × 10 6 breast cancer cells (86R2 or 99LN) were injected into the right thoracic mammary fat pad (MFP) of 20-week-old female DIO BL6 mice (that is, 15 weeks of feeding starting at 5 weeks old). Cells were injected in 1:1 serum-free DMEM/growth factor-reduced Matrigel (BD Biosciences). Tumour volume was measured by digital calliper and calculated as V = (L × W 2 )/2. Key time points throughout the trial were: 0 d, prior to tumour cell injection; 14 d, when primary tumours were first palpable; 28 d, before tumours had metastasized to lung; and 56 d, when lung micro-metastases were first evident. To assess spontaneous metastasis to lung, mice were euthanized at the 56 d time point, and lungs were perfused through the trachea with 10% formalin, paraffin-embedded, and stained with H&E. Tissue sections (10 mm 3 ) were scanned (that is, whole-lung cross-sections) and micro-metastases were counted manually using a Leica Aperio digital pathology slide scanner and analysis software. Primary tumour growth and spontaneous metastasis experiments were approved by RARC and IACUC and were performed in a manner compliant with all relevant ethical regulations regarding animal research.
Experimental metastasis assay.
To investigate the effects of obesity on experimental metastasis to lung, 2 × 10 6 99LN breast cancer cells labelled with GFP and luciferase (GFP-Luc) were injected into the tail vein of 20-week-old female DIO BL6 mice, or 11-week-old ob/ob mice. Cells were resuspended in calcium-and magnesiumfree PBS, and filtered through a 40 µm mesh immediately prior to injection. Lung metastases were monitored for 48 h or 5 weeks using bioluminescent imaging (BLI; Xenogen IVIS-200 Optical In Vivo Imaging System). Luminescence was normalized to day 0 for each individual mouse, to account for any differences in injection efficiency between animals. Experimental metastasis experiments were approved by RARC and IACUC and were performed in a manner compliant with all relevant ethical regulations regarding animal research.
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Neutralization of Gr1 or GM-CSF in vivo.
To target neutrophils in the DIO model, 5-week-old female WT BL6 mice were enrolled on HF or LF diet for 15 weeks, followed by antibody-mediated neutralization of Gr1 (6 µg g −1 body weight anti-Gr1 dosed every 3 d intraperitoneally, clone RB6-8C5, rat IgG2b isotype control; Tonbo Biosciences 9 ) 3 d and 1 d prior to tail vein injection of 99LN breast tumour cells (2 × 10 6 cells). This dosing regimen was confirmed by flow cytometry to efficiently deplete neutrophils in blood, spleen and lung for at least 3 d after each dose (that is, prior to and during the 48 h metastasis assay), using a Ly6C antibody that does not compete with the target antigen. The experimental metastasis assay was performed as described. For neutralization of GM-CSF, the same dosing regimen was used (16 µg g −1 body weight anti-GM-CSF dosed every 3 d intraperitoneally, clone MP122E9, rat IgG2a isotype control; R&D Systems 66 ). Antibody neutralization experiments were approved by RARC and IACUC and were performed in a manner compliant with all relevant ethical regulations regarding animal research.
Recombinant GM-CSF preclinical trial. To test whether GM-CSF alone is capable of modulating lung neutrophils, 5-week-old female WT BL6 mice enrolled on normal chow were treated with recombinant mouse GM-CSF (R&D Systems, 50 µg kg −1 , i.p. every day for 5 d, versus PBS control). After 5 d, mice were either euthanized and lung tissues harvested for flow cytometry analysis, or subjected to tail vein injection of 99LN breast tumour cells (2 × 10 6 ) for the 48 h experimental metastasis assay. During the experimental metastasis assay, mice were dosed via daily administration of GM-CSF. Recombinant protein treatment experiments were approved by RARC and IACUC and were performed in a manner compliant with all relevant ethical regulations regarding animal research.
Serum collection from mice and humans. To collect serum from DIO mice, blood was collected by submandibular bleeding into Eppendorf tubes and allowed to clot at room temperature for ∼20 min. Samples were centrifuged at 2,000g , 4 • C, 10 min. Supernatant was transferred to a polypropylene tube either individually or pooled. For pooled serum, three individual mouse samples were combined and stored at In vitro myelopoiesis assay. To harvest bone marrow cells, femurs and tibiae from WT BL6 mice were flushed under sterile conditions. Cells were filtered through a 40 µm mesh and cultured in Teflon bags (PermaLife PL-30) for 6 d in DMEM supplemented with 5% FBS, or 5% serum derived from either LF/HF mice or lean/obese humans. Recombinant proteins (CCL25, CD40L, GM-CSF, IGFBP2, IL5, IL6, MMP3, MMP9, 100 ng ml −1 for all; R&D Systems) or neutralization antibodies (IgG versus anti-GM-CSF, 0.1 µg ml −1 ) were added as indicated. Treatment media were changed every other day. After 6 d, flow cytometry was performed using antibodies against murine CD45, CD11b and Gr1 (see Supplementary  Table 3 ).
Cytokine arrays. Cytokine arrays were purchased from RayBiotech (Mouse Cytokine Array G2000 and Human Cytokine Array G4000). The mouse G2000 series detects 144 cytokines and the human G4000 series detects 274 cytokines, of which 103 overlapping cytokines were included for downstream analysis. For both species, replicate samples contained pooled serum (9 pooled lean individuals and 10 pooled obese individuals per replicate for human, and 3 pooled animals per replicate for mouse). For each species, 2 independently pooled replicate samples were used, each run in duplicate, and P values were calculated on the basis of these 4 signal outputs. P< 0.05 was considered as statistically significant, and fold cutoff was not used. Both array series were performed according to the manufacturer's instructions. For a complete list of array results, see Supplementary Table 2 .
ELISA analysis of serum GM-CSF and IL5 in mice and humans. Human and Mouse IL5 and GM-CSF Quantikine ELISA kits were obtained from R&D Systems (catalogue no.: Human IL5 no. D5000B; human GM-CSF no. DGM00; mouse IL5 no. M5000; mouse GM-CSF no. MGM00), and ELISAs were performed according to the manufacturer's protocol. An Eppendorf Plate Reader AF2200 was used for colorimetric quantification and analysis at 460 nm and 570 nm wavelengths.
Invasion and migration assays. For invasion assays, growth factor-reduced Matrigel (BD Biosciences) and serum-free DMEM were mixed at a 1:1 ratio, applied to Transwell inserts, and allowed to polymerize for >1 h. Fifty thousand cells were seeded in serum-free DMEM in the upper chamber, and DMEM + 5% FBS was added to the lower chamber. Cell invasion through the Transwell was counted manually after 24 h, by staining with DAPI and mounting. For cell migration assays, the same protocol was followed, except that Transwell chambers were not coated with Matrigel.
Adoptive transfer of neutrophils in vivo. Adoptive cell transfer trial design was based on previously published methods 70 . Schematic representation of the trial design can be found in Fig. 7a . Briefly, bone marrow was collected from n = 10 WT or ob/ob mice, and neutrophils were enriched using a mouse Neutrophil Isolation Kit (Miltenyi Biotec). WT neutrophils were labelled with green fluorescent CellTrace dye and ob/ob neutrophils were labelled with far red fluorescent CellTrace dye (Invitrogen). WT and ob/ob neutrophils were mixed at an equal ratio (confirmed by flow cytometry), and then 3 × 10 6 cells were injected via tail vein into WT, ob/ob or ob/ob mice + neutralizing antibody against IL5 (1 mg kg −1 body weight, dosed 3 d and 1 d prior to adoptive transfer intravenously, clone TRFK5, rat IgG1 isotype control; R&D Systems) 67 . Blood and lungs were collected for flow cytometry after 4 h and 8 h, to evaluate homing and turnover, respectively. Adoptive transfer experiments were approved by RARC and IACUC and were performed in a manner compliant with all relevant ethical regulations regarding animal research.
T-cell CFSE assay. T-cell proliferation was assessed by CFSE (Invitrogen) according to the manufacturer's protocol and published methods 9, 43 . Briefly, CD8+ cytotoxic T cells were isolated from WT mice, stimulated with mouse T-Activator CD3/CD28 Dynabeads (ThermoFisher Scientific) and recombinant IL2 (30 U ml −1 ; R&D Systems), and seeded (8 × 10 4 cells per well of 96-well plate) either alone or in co-culture with lung neutrophils isolated from LF-or HF-fed DIO mice at a ratio of 1:2. Culture media contained RPMI 1640 + 10% heat-inactivated FBS (Gibco), 1% P/S, 10 ml non-essential amino acid supplement, 200 mM L-glutamine, 100 mM sodium pyruvate, 1 M HEPES, and 5 µl β-mercaptoethanol. Co-culture was performed for 4 d prior to flow cytometry analysis of CFSE dye dilution, representing T-cell division.
NK cell cytotoxicity assay. To assess the effect of neutrophils on NK cell cytotoxicity in vitro, NK1.1 + cells were isolated by FACS from peripheral blood of WT BL6 mice, and were co-cultured for 3 d in a low-attachment dish at a 1:1 ratio with LF or HF peripheral neutrophils. Flow cytometry was used to quantify the expression of the degranulation marker CD107a on NK cells in response to co-culture. Culture media contained RPMI 1640 + 10% heat-inactivated FBS (Gibco), 1% P/S, 10 ml nonessential amino acid supplement, 200 mM L-glutamine, 100 mM sodium pyruvate, 1 M HEPES and 5 µl β-mercaptoethanol. To assess the effect of obesity on NK cell cytotoxicity in vivo, flow cytometry was used to quantify peripheral blood NK1.1 + CD107a + cells in tumour-bearing LF or HF mice.
RNA isolation and qRT-PCR. RNA was isolated with Trizol, DNase treated, and 1 µg of RNA was used for cDNA synthesis using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Mouse Taqman probes (Applied Biosystems) were used for quantifying expression of Erbb2
Statistics and reproducibility. GraphPad Prism Pro5 was used for all data analysis. Data are presented as mean ± standard error (s.e.m.) or box and whisker plots (boxplots) unless indicated otherwise, and P < 0.05 was considered as statistically significant. For all boxplots, the centre line is the median value, and the box extends from the 25th to 75th percentile. Whiskers and error bars are defined in the legends. For all representative images, results were reproduced at least 3 times in independent experiments. For all quantitative data, the statistical test used is DOI: 10.1038/ncb3578 indicated in the legends. Briefly, Gaussian distribution was first determined using the D' Agostino-Pearson omnibus normality test. Data that were determined to be parametric were analysed by a two-tailed unpaired Student's t-test (2 groups), or an ordinary one-way ANOVA (>2 groups) with Dunnett's multiple comparisons test (that is, all groups compared with a control) or Bonferroni's multiple comparisons test (that is, select pairwise comparisons). Data that were determined to be nonparametric were analysed by a Mann-Whitney test (2 groups), or Kruskal-Wallis test (>2 groups) with Dunn's multiple comparisons. For animal studies, data were generated from at least 2 independent cohorts. For human weight loss studies, data were analysed by a two-tailed, paired Student's t-test to account for matched preand post-weight loss samples for each individual. All data included in the study are reproducible: all flow cytometry experiments were repeated 3 or more times with similar results; all animal trials were repeated with at least n = 4 in at least 2 independent cohorts with similar results; all in vitro assays were repeated in at least 3 independent experiments with similar results.
Data availability. All data are available from the authors upon reasonable request. Statistical source data for Figs 2a, 4b,c,e, 5e-g and 8a-c,e,f and Supplementary  Fig. 1c,d and Supplementary Fig. 2e 
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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Policy information about availability of computer code 10 . Eukaryotic cell lines a. State the source of each eukaryotic cell line used. Breast tumor cell lines were isolated from the MMTV-PyMT mouse model, backcrossed into the BL6 background for >10 generations. These cell lines were subsequently selected for their capacity to grow in the mammary fat pad (7x105 cells injected/mouse) of WT BL6 animals within a reasonable time period (<2 months). Three cell lines were selected for subsequent experiments, including 99LN, 86R2, and 91R2. All breast tumor cell lines in culture were maintained in DMEM supplemented with 10% FBS, and were validated to be mycoplasma-free. For assays involving immune cell culture, primary cells were isolated from peripheral sources (i.e. blood or bone marrow) by FACS and used immediately for functional assays, for example NK cell co-culture or T cell CFSE.
b. Describe the method of cell line authentication used. Cell line authentication was not needed -all cell lines from this study were generated in-house for immediate downstream application.
c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines were confirmed to be mycoplasma negative.
d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample.
myeloid cells with high side scatter, and Siglec-f+. In some cases, further gating on IL5ra+ or Ki67+ populations was performed for eosinophils, monocytes, and neutrophils as defined here. For CFSE assays, bulk T cells were gated as CD45+CD3+ and then further gating according to positive CD4 or CD8 status for helper and cytotoxic T cells, respectively. For NK cell cytotoxicity assays, NK cells were defined as CD45+ with low side scatter, NK1.1+. Gating on CD107a+ populations was used to further define NK cells with cytotoxic function.
Human gating strategy: In all cases, dead cells and debris were excluded from analyses using FSC x SSC and DAPI. CD45+ was used as a marker for total leukocytes, CD11b+ was used as a marker for myeloid cells. Gating strategy using cell surface markers were as follows: Peripheral blood neutrophils (CD45+CD11b+CD66b+CD16 +CD14lo), eosinophils (CD45+CD11b+CD66b+CD16-CD14lo), nonclassical monocytes (CD45+CD11b+CD66b-CD16+CD14lo), intermediate monocytes (CD45+CD11b+CD66b-CD16+CD14hi), and classical monocytes (CD45+CD11b+CD66b-CD16-CD14+).
Gating on IL5R+ cells was also included in analysis for each population. Eosinophils were used as a positive gating control for IL5R positivity as this is a canonical marker/signaling pathway for this cell type.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
